Status of combination drugs with betamethasone dipropionate and salicylic acid in the treatment of skin diseases

Postepy Dermatologii i Alergologii

Volumn 29, Issue 3, 2012, Pages 196-204

  Pastuszka, Marta ^a   Kaszuba, Andrzej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Betamethasone dipropionate; Mechanism of action; Salicylic acid; Therapy

Indexed keywords

BETAMETHASONE DIPROPIONATE; BUDESONIDE; CALCIPOTRIOL; CLOBETASOL; DEXAMETHASONE ACETATE; FLUMETASONE PIVALATE; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 13; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; SALICYLIC ACID;

ACNE; ADRENAL INSUFFICIENCY; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ATROPY; BLOOD PRESSURE; CATARACT; CELL MIGRATION; CONTACT ALLERGY; CUSHING SYNDROME; DNA SEQUENCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; EPIDERMIS; ERYTHEMA; FOLLICULITIS; GLAUCOMA; HUMAN; HYPERGLYCEMIA; HYPERKERATOSIS; IMMUNOSUPPRESSIVE TREATMENT; LICHEN PLANUS; LUPUS ERYTHEMATOSUS; LYSOSOME MEMBRANE; MACROPHAGE; NAIL PSORIASIS; NONHUMAN; OSTEOPOROSIS; PARAPSORIASIS; PEPTIC ULCER; PERIORAL DERMATITIS; PSORIASIS; PSORIASIS VULGARIS; REVIEW; SEBORRHEIC DERMATITIS; SIDE EFFECT; SKIN DISCOLORATION; TELANGIECTASIA; VASOCONSTRICTION;

EID: 84864869249     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Necela BM, Cidlowski JA. Mechanisms of glucocorticoid receptor action in noninflammatory and inflammatory cells. Am Thorac Soc 2004; 1: 239-46.
2. Grzanka A. Molekularny mechanizm działania glikokortykosteroidów. Pol Arch Med Wewn 1996; 95: 375-82.
3. Piotrkowska B, Droszcz W. Glikokortykosteroidy. In: Farmakoterapia chorób alergicznych. Chyrek-Borowska S, Wiśniewski K (eds.). PZWL, Warszawa 1993; 71-83.
4. Schacke H, Schottelius A, Docke WD, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. PNAS 2004; 101: 227-32. (Pubitemid 38084232)
5. Ahluwalia A. Topical glucocorticosteroids and the skin-mechanisms of action: an update. Med Inflam 1998; 7: 183-93. (Pubitemid 28338148)
6. Appelton I. Induction of cyclo-oxygenase and nitric oxide synthase in inflammation. Adv Pharmacol 1996; 35: 27-79.
7. Silny W, Czarnecka-Operacz M. Działania niepoża̧dane miejscowych preparatów glikokortykosteroidowych stosowanych w dermatologii. Postep Derm Alergol 2003; 1: 30-6.
8. Hoetzenecker W, Meingassner JG, Ecker R, et al. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epiderma Langerhans cells. J Invest Dermatol 2004; 122: 673-84. (Pubitemid 38471336)
9. Belvisi MG, Wicks SL, Battram CH, et al. Therapeutic benefits of dissociated glucocortcosteroids and the relevance of in vitro separation of transrepression from transactivation. J Immunol 2001; 166: 1975-82. (Pubitemid 32114685)
10. Lavker RM, Schechter NM, Lazarus GS. Effects of TCS on human dermis. Br J Dermatol 1986; 115: 101-7.
11. Yohn JJ, Weston WL. Topical glucocorticosteroids. Curr Probl Dermatol 1990; 2: 31-63.
12. Ayres PJ, Hooper G. Assessment of the skin penetration properties of different carrier vehicles for topically applied cortisol. Br J Dermatol 1978; 99: 307-17. (Pubitemid 9008787)
13. Aalto-Korte K, Turpeinen M. Pharmacokinetics of topical hydrocortisone at plasma level after applications once or twice daily in patients with widespread dermatitis. Br J Dermatol 1995; 133: 259-63.
14. Hill CJH, Rostenberg A. Adverse effects from topical steroids. Cutis 1978; 3: 624-8. (Pubitemid 8340477)
15. Lubach D, Bensmann A, Bonemann U. Steroid-induced dermal atrophy: investigations on discontinuous application. Dermatologica 1989; 179: 67-72. (Pubitemid 19223924)
16. Feldman SR. Tachyphylaxis to topical coricosteroids: the more you use them, the less they work? Clin in Dermatol 2006; 24: 229-30. (Pubitemid 43728108)
17. Going SM, Guyer BM, Jarvie, DR. Salicylic acid gel for scalp psoriasis. Clin Expl Dermatol 1986; 11: 260-2. (Pubitemid 16082051)
18. Gottfried W. Psoriasis treatment in difficult localizations: scalp, nails, and intertriginous area. Clin Dermatol 2008; 26: 448-59.
19. Ahluwalia A. Topical glucocorticosteroids and the skin-mechanisms of action: an update. Med Inflam 1998; 7: 183-93. (Pubitemid 28338148)
20. Hillström L, Pettersson L, Svensson L. Comparison of betamethasone dipropionate lotion with salicylic acid (Diprosalic®) and clobetasol propionate lotion (Dermovate®) in the treatment of psoriasis of the scalp. J Int Med Res 1982; 10: 419-22. (Pubitemid 13247447)
21. Chattopadhyay SP, Arora PN, Anand S, et al. Betamethasone dipropionate (0,05%) plus salicylic acid (3%) ointment versus dexamethasone acetate (1%) and salicylic acid 4% ointments in chronic dermatoses. Indian J Dermatol 1967; 32: 41-4.
22. Landi G. A clinical investigation of a new topical corticosteroid penetration: betamethasone dipropionate with salicylic acid. Pharmatherapeutica 1977; 1: 442-6. (Pubitemid 8213779)
23. Gip L. Betamethasone dipropionate and salicylic acid in the treatment of psoriasis and seborrheic dermatitis. Acta Therap 1981; 7: 283-9.
24. Heunknown signvding G. Treatment of psoriasis of the scalp with betamethasone 17, 21-dipropionate plus salicylic acid lotion ('Diprosalic'). Pharmatherapeutica 1981; 3: 61-6.
25. Gisslen H, Nordin P. A comparative study of two potent corticosteroid preparations in the treatment of psoriasis. Pharmatherapeutica 1979; 2: 173-6. (Pubitemid 9205860)
26. Gisslen H, Nordin P. A comparative study of two potent corticosteroid preparations in the treatment of psoriasis. Pharmatherapeutica 1979; 2: 178.
27. Scarpa C. Calcipotriol: clinical trial versus betamethasone dipropionate + salicylic acid. Acta Derm Venereol Suppl (Stockh) 1994; 186: 47. (Pubitemid 24208149)
28. Kuokkanen K, Zador G. A double-blind comparison of betamethasone dipropionate with salicylic acid (Diprosalic) and budesonide ointment in the treatment of psoriasis. Cur Ther Res 1983; 34: 459-68. (Pubitemid 14231541)
29. Elie R, Durocher LP, Kavalec E. Effect of salicylic acid on the activity of betamethasone-17,21-dipropionate in the treatment of erythematous squamous dermatoses. J Int Med Res 1983; 11: 108-12. (Pubitemid 13118504)
30. Fredriksson T. Studies with betamethasone dipropionate plus salicylic acid (Diprosalic) in psoriasis. Pharmatherapeutica 1976; 1: 277-83.
31. Eriksson G. Betamethasone 17,21-dipropionate with salicylic acid, a double-blind evaluation. J Int Med Res 1975; 3: 368-70.
32. Malfitan V. Betamethasone dipropionate and salicylic acid lotion for nonscalp dermatoses. Clin Ther 1983; 5: 290-6.
33. Nolting S, Hagemeier HH. Therapy of erythrosquamous dermatoses: betamethasone dipropionate plus salicylic acid in comparison with betamethasone dipropionate solution. Fortschr Med 1983; 101: 1679-83. (Pubitemid 13006084)
34. Tosti A, Piraccini BM, Cameli N, et al. Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998; 139: 655-9. (Pubitemid 28474312)
35. Juszkiewicz-Borowiec M. Miejscowa sterydoterapia w chorobach skóry. Nowa Med 2000; 11: 40-2.
36. Lagos BR, Maibach HJ. Frequency of application of topical corticosteroids: an overview. Br J Dermatol 1998; 139: 763-6. (Pubitemid 28520280)
37. Kao JS. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003; 120: 456-64. (Pubitemid 36298433)
38. Gip L, Hamfelt A. Percutaneous absorption of bethametasone-17,21- dipropionate and salicyli acid in the treatment of psoriasis and eczema. J Int Med Res 1976; 4: 106.
39. Żaba R, Mikołajczyk K. Miejscowe preparaty glikokortykosteroidowe - zasady racjonalnego stosowania. Przew Lek 2004; 6: 61-9.
40. Furue M. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol 2003; 148: 128-33. (Pubitemid 36114873)